Ben Zimmer, Priovant CEO
June 28, 2022 06:18 AM EDT
Startups

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

Amber Tong

In No­vem­ber, Pfiz­er dis­closed it’s spun out the Phase II dual JAK1/TYK2 in­hibitor to a start­up formed in col­lab­o­ra­tion with an un­named, ex­pe­ri­enced part­ner. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

A service from the Financial Times